MLYS240719C15000
- 0.35
- 0.000.00%
Mineralys Therapeutics Newsroom
Mineralys Therapeutics Analyst Ratings
Buy Rating Justified by Mineralys Therapeutics' Promising Hypertension and CKD Drug Lorundrostat
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Anika Therapeutics (ANIK)
Mineralys Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Resmed (RMD), Mineralys Therapeutics, Inc. (MLYS) and Addus Homecare (ADUS)
Buy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic Developments
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX) and Mineralys Therapeutics, Inc. (MLYS)
Credit Suisse Maintains Outperform on Mineralys Therapeutics, Lowers Price Target to $37
Mineralys Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Eli Lilly & Co (LLY)
Mineralys Therapeutics, Inc. (MLYS) Gets a Buy From Credit Suisse
Credit Suisse Reiterates Outperform on Mineralys Therapeutics, Maintains $38 Price Target
Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Cara Therapeutics (CARA) and Mineralys Therapeutics, Inc. (MLYS)
Credit Suisse Adjusts Mineralys Therapeutics' Price Target to $38 From $40, Keeps Outperform Rating
Credit Suisse Maintains Outperform on Mineralys Therapeutics, Lowers Price Target to $38
Analysts Offer Insights on Healthcare Companies: Aravive (ARAV), Prelude Therapeutics (PRLD) and Mineralys Therapeutics, Inc. (MLYS)
Credit Suisse Starts Mineralys Therapeutics at Outperform With $40 Price Target, Says Potential Near-Term Partnership Could Boost Stock Value
Stifel Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $45
Analysts Are Bullish on Top Healthcare Stocks: Unity Biotechnology (UBX), Mineralys Therapeutics, Inc. (MLYS)